Evidence map›Paper›PMID 38809456›Full record

ArticleAnnals of hematology2024

BeEAM vs. BEAM: evaluating conditioning regimens for autologous stem cell transplantation in patients with relapsed or refractory DLBCL.

Ruiqi Wang, Xinghe Shangguan, Zhenxing Zhu, Dan Cong, Yuansong Bai, Wenlong Zhang

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ruiqi WangDepartment of Hematology and Oncology, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
Xinghe ShangguanDepartment of Hematology, The First Affiliated Hospital of Dalian Medical University, 222 Zhongshan Road, Dalian, 116021, China.
Zhenxing ZhuDepartment of Hematology and Oncology, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
Dan CongDepartment of Hematology and Oncology, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
Yuansong BaiDepartment of Hematology and Oncology, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
Wenlong ZhangDepartment of Hematology and Oncology, China-Japan Union Hospital of Jilin University, Changchun, 130033, China. wenxu@jlu.edu.cn.ORCID http://orcid.org/0000-0002-9159-2747

Funding

Science and Technology Development Project of Jilin Province 20210401174YY
6 · The paper itself

Abstract

purposeTo evaluate whether BeEAM is an alternative to BEAM for autologous stem cell transplantation (ASCT) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

methodsData of 60 patients with relapsed or refractory DLBCL who underwent ASCT from January 2018 to June 2023 in our center, including 30 patients in the BeEAM group and 30 patients in the BEAM group, were retrospectively analyzed. The time to hematopoietic reconstitution, treatment-related adverse events, number of hospitalization days, hospitalization cost, and survival benefit were compared between the two groups.

resultsThe clinical characteristics of the patients did not significantly differ between the two groups. The median number of reinfused CD34 + cells was 5.06 × 10

conclusionAs a conditioning regimen for relapsed or refractory DLBCL, BeEAM has a desirable safety profile and is well tolerated, and its hematopoietic reconstitution time, number of hospitalization days, and survival benefit are not inferior to those of BEAM. BeEAM has a lower hospitalization cost and is an alternative to BEAM.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsHematopoietic Stem Cell TransplantationLymphoma, Large B-Cell, DiffuseTransplantation, AutologousTransplantation ConditioningAdultAgedCarmustineCyclophosphamideCytarabineEtoposideFemaleHumansMaleMelphalanMiddle AgedCarmustineCyclophosphamideCytarabineEtoposideMelphalanAutologous stem cell transplantationConditioning regimenDiffuse large B-cell lymphoma

Identifiers

PMID38809456

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.